INTERNATIONAL PATENT: IMMUNEONCO BIOPHARMACEUTICALS (SHANGHAI) INC., 宜明昂科生物医药技术(上海)股份有限公司 FILES APPLICATION FOR "RECOMBINANT FUSION PROTEIN TARGETING CD38 AND CD47"

GENEVA, Sept. 16 -- IMMUNEONCO BIOPHARMACEUTICALS (SHANGHAI) INC. (Building 15, Lane 1000, Zhangheng RoadPudong New Area, Shanghai 201203), 宜明昂科生物医药技术(上海)股份有限公司 (中国上海市浦东新区张衡路1000弄15号) filed a patent application (PCT/CN2025/081165) for "RECOMBINANT FUSION PROTEIN TARGETING CD38 AND CD47" on Mar 07, 2025. With publication no. WO/2025/185723, the details related to the patent application was published on Sep 11, 2025.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, ...